These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Assessment of vaccine potential of the Neisseria-specific protein NMB0938. Sardiñas G; Climent Y; Rodríguez Y; González S; García D; Cobas K; Caballero E; Pérez Y; Brookes C; Taylor S; Gorringe A; Delgado M; Pajón R; Yero D Vaccine; 2009 Nov; 27(49):6910-7. PubMed ID: 19751688 [TBL] [Abstract][Full Text] [Related]
45. The challenge of post-implementation surveillance for novel meningococcal vaccines. Snape MD; Medini D; Halperin SA; DeTora L; Drori J; Moxon ER Vaccine; 2012 May; 30 Suppl 2():B67-72. PubMed ID: 22230578 [TBL] [Abstract][Full Text] [Related]
46. Enhanced surveillance of invasive meningococcal disease in Canada: 1 January, 2002, through 31 December, 2003. Can Commun Dis Rep; 2006 Apr; 32(8):97-107. PubMed ID: 16685767 [No Abstract] [Full Text] [Related]
47. Conjugate vaccine-induced immunological priming is not protective against acute meningococcal C infection. Spoulou VI; Moschou CK; Tzanakaki G; Theodoridou MC Vaccine; 2007 Oct; 25(41):7012-3. PubMed ID: 17707961 [No Abstract] [Full Text] [Related]
48. Improved OMV vaccine against Neisseria meningitidis using genetically engineered strains and a detergent-free purification process. van de Waterbeemd B; Streefland M; van der Ley P; Zomer B; van Dijken H; Martens D; Wijffels R; van der Pol L Vaccine; 2010 Jul; 28(30):4810-6. PubMed ID: 20483197 [TBL] [Abstract][Full Text] [Related]
49. Meningococcal B vaccine development and evaluation of efficacy. van Alphen L; van den Dobbelsteen G Hum Vaccin; 2008; 4(2):158-61. PubMed ID: 18388494 [TBL] [Abstract][Full Text] [Related]
50. The New Zealand Meningococcal Vaccine Strategy: a tailor-made vaccine to combat a devastating epidemic. Sexton K; Lennon D; Oster P; Crengle S; Martin D; Mulholland K; Percival T; Reid S; Stewart J; O'Hallahan J N Z Med J; 2004 Aug; 117(1200):U1015. PubMed ID: 15475985 [TBL] [Abstract][Full Text] [Related]
51. Phase II meningococcal B vesicle vaccine trial in New Zealand infants. Jackson C; Lennon DR; Sotutu VT; Yan J; Stewart JM; Reid S; Crengle S; Oster P; Ypma E; Aaberge I; Mulholland K; Martin DR Arch Dis Child; 2009 Oct; 94(10):745-51. PubMed ID: 18838420 [TBL] [Abstract][Full Text] [Related]
52. Universal protein vaccines against Neisseria meningitidis serogroup B, Streptococcus pneumoniae and influenza. Principi N; Esposito S Hum Vaccin; 2011 Sep; 7(9):905-12. PubMed ID: 21865879 [TBL] [Abstract][Full Text] [Related]
53. Prevalence and sequence variations of the genes encoding the five antigens included in the novel 5CVMB vaccine covering group B meningococcal disease. Jacobsson S; Hedberg ST; Mölling P; Unemo M; Comanducci M; Rappuoli R; Olcén P Vaccine; 2009 Mar; 27(10):1579-84. PubMed ID: 19162117 [TBL] [Abstract][Full Text] [Related]
54. Authors' response: Meningococcal vaccine antigen diversity in global databases. Brehony C; Hill DM; Lucidarme J; Borrow R; Maiden MC Euro Surveill; 2016 Apr; 21(15):. PubMed ID: 27104935 [No Abstract] [Full Text] [Related]
57. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Oster P; Lennon D; O'Hallahan J; Mulholland K; Reid S; Martin D Vaccine; 2005 Mar; 23(17-18):2191-6. PubMed ID: 15755593 [TBL] [Abstract][Full Text] [Related]
58. A prospective study of the effectiveness of the New Zealand meningococcal B vaccine. Kelly C; Arnold R; Galloway Y; O'Hallahan J Am J Epidemiol; 2007 Oct; 166(7):817-23. PubMed ID: 17615088 [TBL] [Abstract][Full Text] [Related]
59. Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines. Trotter CL; Ramsay ME FEMS Microbiol Rev; 2007 Jan; 31(1):101-7. PubMed ID: 17168998 [TBL] [Abstract][Full Text] [Related]